Autopsy report · NCT02658877

Sputum-derived Cellular Targets After Xolair (Omalizumab)

“Difficulty recruiting subjects”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 6 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

NYU Langone Health

Sponsor type

University, hospital or other

Conditions

Asthma

Interventions

Omalizumab; Placebo

Participants

3

Sites

1

Countries

United States

Trials that died the same way

• Pilot Study of Skin Quality Improvement After Adipose-drived Stem Cell Transfer in Irradiated Breasts
  “Difficulty in recruiting research subjects” (88% match in meaning)
• Home Program Education for Patients With Low Back Pain
  “Not recruiting subjects currently” (85% match in meaning)
• In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
  “Not able to recruit subjects” (85% match in meaning)
• Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes
  “Unable to recruit any subjects” (83% match in meaning)
• FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
  “inability to recruit subjects” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.